Navigation Links
Cell Biosciences Introduces Kits for Oncoprotein Analysis
Date:1/21/2009

PALO ALTO, Calif., Jan. 21 /PRNewswire/ -- Cell Biosciences, Inc., a provider of nanoproteomic analysis systems to life science researchers, today announced the launch of its first kits for the analysis of specific oncoproteins on the Firefly(TM) 3000 Protein Analysis System. The new kits are optimized for characterization of proteins in the MEK and ERK families, which play critical roles in cancer cell survival and proliferation. Drug developers have targeted signaling via MEK and ERK with a number of kinase inhibitor anticancer drugs.

The Firefly 3000 system is an ultrasensitive nanofluidic immunoassay system designed to analyze extremely small biological samples. Traditional protein analysis techniques can require as many as 100,000 cells, which generally precludes protein analysis in precious clinical samples. By using the new analysis kits on the Firefly 3000 system, researchers can obtain detailed profiles of MEK and ERK signaling in as few as 25 cells. Subtle effects of kinase inhibitor drugs on MEK and ERK phosphorylation can be studied in cancer cells and solid tumor samples.

"We developed these oncoprotein analysis kits in response to strong interest from our cancer research customers," said Wilhelm Lachnit, Ph.D., Vice President of Research and Development. "They enable robust analysis of MEK and ERK phosphoprotein signaling, and provide a unique window into the specific actions of kinase inhibitor drugs in limited samples."

About Cell Biosciences

Cell Biosciences is a private life sciences company focused on nanoproteomics. We develop instrumentation systems and assays for the measurement of phosphoprotein signaling and activation in extremely small biological samples. Our company's lead product is a capillary-based nano-fluidic immunoassay platform that provides quantitative and reproducible data on key signaling pathways in precious biological samples, such as small tumor biopsies and stem cells. Cell Biosciences is located in Palo Alto, California.

http://www.cellbiosciences.com

info@cellbiosciences.com


'/>"/>
SOURCE Cell Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
2. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
3. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
4. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
5. Cell Biosciences Delivers Next Generation System to Stanford University
6. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
7. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
8. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
9. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
10. Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System
11. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced today ... demand KbioBox developed a sophisticated “3 click” gene dditing off target analysis program ... new website, https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. ...
(Date:12/8/2016)... Dec. 8, 2016  Soligenix, Inc. (OTCQB: SNGX) ... focused on developing and commercializing products to treat ... need, announced today the long-term follow-up data from ... a first-in-class Innate Defense Regulator (IDR), in the ... neck cancer patients undergoing chemoradiation therapy (CRT).  The ...
(Date:12/8/2016)... 2016 Eutilex Co. Ltd. today announced that ... Series A financing. This financing round included participation from ... SNU Bio Angel. This new funding brings the total ... $27.7M) since its founding in 2015. ... and commercialization of its immuno-oncology programs, expand its R&D ...
(Date:12/7/2016)... ... 07, 2016 , ... A new study published in the ... treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for ... blood sampling may improve the value of a blood-based test.” The study was ...
Breaking Biology Technology:
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/17/2016)... OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it has ... using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer storage ... ... ... Setting up ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
Breaking Biology News(10 mins):